Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Rhea-AI Summary
Praxis Precision Medicines (Nasdaq: PRAX) announced on April 1, 2026 that its Compensation Committee granted restricted stock unit awards covering an aggregate of 3,558 shares to eighteen new non-executive employees under the 2024 Inducement Plan.
The awards were granted as inducements under Nasdaq Listing Rule 5635(c)(4) and vest in four equal annual installments, subject to continued employment on each vesting date.
Positive
- None.
Negative
- None.
News Market Reaction – PRAX
On the day this news was published, PRAX declined 0.09%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
PRAX was down 0.9% with mixed moves across key biotech peers: AVXL up 0.65%, NKTR up 3.6%, SANA up 3.39%, while EYPT and ZBIO were modestly negative. Only SANA appeared on the momentum scanner, reinforcing a stock-specific context around PRAX.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Mar 30 | Regulatory milestone | Positive | +16.6% | FDA accepted relutrigine NDA with priority review and set PDUFA date. |
| Mar 04 | Employee inducement grants | Neutral | -4.5% | RSU awards for 2,931 shares to new employees under 2024 Inducement Plan. |
| Feb 19 | Earnings and update | Positive | +0.8% | Reported 2025 results, strong cash position, and two NDA submissions. |
| Feb 09 | Earnings date & conferences | Neutral | +0.3% | Scheduled Q4/FY 2025 call and participation in upcoming conferences. |
| Feb 04 | Employee inducement grants | Neutral | +0.8% | RSU awards for 2,964 shares to new employees under 2024 Inducement Plan. |
Recent news has consistently aligned with price moves, with positive regulatory and earnings updates followed by gains and routine inducement grants drawing modest, mixed reactions.
Over the past two months, Praxis has reported several major milestones. On Feb 19, 2026, Q4 and full-year 2025 results highlighted $926.1M in cash and $621.2M in January 2026 net proceeds, alongside two NDA submissions. On Mar 30, 2026, the FDA accepted the NDA for relutrigine with priority review, driving a 16.55% move. In parallel, recurring inducement grant releases under the 2024 Inducement Plan have involved relatively small RSU awards and produced limited stock impact.
Market Pulse Summary
This announcement details routine inducement grants of 3,558 restricted stock units to 18 new non-executive employees under the 2024 Inducement Plan, vesting over four years. It adds modest, service-based equity compensation on top of recent transformative milestones, including NDA submissions and priority review for relutrigine. Investors may contextualize these grants alongside Praxis’s strong cash position, late-stage CNS pipeline, and prior inducement disclosures when tracking overall equity issuance and governance practices.
Key Terms
restricted stock unit financial
nasdaq listing rule 5635(c)(4) regulatory
equity awards financial
AI-generated analysis. Not financial advice.
BOSTON, April 02, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (Nasdaq: PRAX), a fully integrated, leading central nervous system (CNS) precision neuroscience biopharmaceutical company, today announced that on April 1, 2026, the Compensation Committee of Praxis’ Board of Directors granted restricted stock unit awards covering an aggregate of 3,558 shares of its common stock to eighteen new non-executive employees under the Praxis Precision Medicines, Inc. 2024 Inducement Plan (the 2024 Inducement Plan). The restricted stock unit awards were granted as inducements material to the employees’ entering into employment with Praxis in accordance with Nasdaq Listing Rule 5635(c)(4).
The 2024 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously employees of Praxis, or following a bona fide period of non-employment, as an inducement material to such individuals’ entering into employment with Praxis, pursuant to Nasdaq Listing Rule 5635(c)(4).
The restricted stock units will vest in four equal annual installments, subject to the employee’s continued employment with Praxis on each vesting date.
About Praxis
Praxis Precision Medicines is a fully integrated, leading CNS precision neuroscience biopharmaceutical company, translating insights from genetic epilepsies into the development of therapies for CNS disorders characterized by neuronal excitation-inhibition imbalance. Praxis is applying genetic insights to the discovery and development of therapies for rare and more prevalent neurological disorders through our proprietary small molecule platform, Cerebrum™, and antisense oligonucleotide (ASO) platform, Solidus™, using our understanding of shared biological targets and circuits in the brain. Praxis has established a diversified, multimodal CNS portfolio including multiple programs across movement disorders and epilepsy, with four late-stage product candidates. For more information, please visit www.praxismedicines.com and follow us on Facebook, LinkedIn and Twitter/X.
Contacts: Investor Contact: Praxis Precision Medicines investors@praxismedicines.com 857-702-9452 Media Contact: Dan Ferry LifeSci Advisors Daniel@lifesciadvisors.com 617-430-7576